作者
Sunil Kumar Surapaneni, Nilkumar Patel, Li Sun, Nagavendra Kommineni, Anil Kumar Kalvala, Aragaw Gebeyehu, Peggy Arthur, Leanne C Duke, Ramesh Nimma, David G Meckes Jr, Mandip Singh
发表日期
2022/11
期刊
Drug delivery and translational research
卷号
12
期号
11
页码范围
2762-2777
出版商
Springer US
简介
To date, promising therapy for triple negative breast cancer (TNBC) remains a serious concern clinically because of poor prognosis, resistance, and recurrence. Herein, anti-cancer potential of synthetic cannabidiol (CBD; Purisys, GA; GMP grade) was explored either alone or as a chemosensitizer followed by post-treatment with doxorubicin (DOX) in TNBC (i.e., MDA-MB-231 and MDA-MB-468) cells. In comparison to 2D cultures, CBD showed greater IC50 values in 3D (LDP2 hydrogel based) cultures of MDA-MB-231 (6.26-fold higher) and MDA-MB-468 (10.22-fold higher) cells. Next-generation RNA sequencing revealed GADD45A, GADD45G, FASN, LOX, and integrin (i.e., -α5, -β5) genes to be novelly altered by CBD in MDA-MB-231 cells. CIM-16 plate-based migration assay and western blotting disclosed that CBD induces anti-migratory effects in TNBC cells by decreasing fibronectin, vimentin, and integrins-α5 …
学术搜索中的文章
SK Surapaneni, N Patel, L Sun, N Kommineni… - Drug delivery and translational research, 2022